림프종 치료 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of lymphoma treatment Market

The global lymphoma treatment market size was valued at USD 8.11 billion in 2025. The market is projected to grow from USD 8.88 billion in 2026 to USD 18.30 billion by 2034. Increasing lymphoma prevalence, rising demand for advanced cancer therapies, and continuous investments in research and development are supporting market growth. North America dominated the lymphoma treatment market with a 47.98% share in 2025, supported by advanced healthcare infrastructure, high adoption of innovative therapeutics, and strong clinical research activity.

Market Definition and Scope

Lymphoma is a major form of blood cancer affecting the lymphatic system and includes Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment approaches include immunotherapy, targeted therapy, chemotherapy, and other supportive or combination therapies. Increasing clinical research into difficult-to-treat lymphoma types is encouraging the development of innovative drug candidates, including advanced immune-based and targeted treatments.

Market Dynamics

Drivers

Rising Cases of Lymphoma

The increasing prevalence of lymphoma and other blood cancers is generating greater demand for effective therapeutic products. Because certain lymphomas may remain difficult to identify until advanced stages, patients can require intensive treatment, increasing the need for innovative therapies and improved treatment approaches.

High Cure Rates of Certain Lymphomas

Advances in diagnosis and treatment have improved outcomes for several lymphoma types. Better early detection and the availability of therapies capable of producing favorable responses are encouraging greater adoption of lymphoma therapeutics and supporting continued investment in new treatment options.

Trends

Prominent Pipeline Products

Growing involvement of pharmaceutical and biotechnology companies in research and development is a major market trend. Companies are developing pipeline candidates for difficult-to-treat lymphoma types, while clinical trials and regulatory designations are supporting innovation. Increasing development of immunotherapies and targeted therapies is expected to expand treatment options through 2034.

Restraints

High Costs of Certain Therapeutics

The high cost of advanced lymphoma therapies can restrict treatment access, particularly in emerging economies. Limited affordability, inadequate reimbursement mechanisms, and lower treatment rates can prevent eligible patients from receiving expensive immunotherapies and other advanced therapeutic products.

Segmentation Analysis

By Therapy

The market is segmented into immunotherapy, targeted therapy, chemotherapy, and others. Immunotherapy is expected to remain the leading treatment segment due to strong clinical outcomes and increasing adoption of advanced immune-based therapies. The segment is projected to generate USD 7.07 billion in 2025. Targeted therapy represents another important segment because of its ability to selectively address cancer cells, while chemotherapy remains an established treatment approach.

By Disease Type

Based on disease type, the market is divided into non-Hodgkin lymphoma and Hodgkin lymphoma. Non-Hodgkin lymphoma is expected to dominate because it represents the majority of lymphoma cases and has a broad range of treatment requirements. Hodgkin lymphoma represents a smaller portion of the market, although continued therapeutic innovation is expected to improve its treatment landscape.

By Distribution Channel

The market includes retail pharmacies, hospital pharmacies, and online pharmacies. Hospital pharmacies represent a major distribution channel because many lymphoma treatments require administration and monitoring within healthcare facilities. The hospitals and retail pharmacies segment is expected to hold a 60.1% share in 2025. Online pharmacies are also gaining importance for patients requiring regular chronic-care medicines.

Regional Insights

North America

North America dominated the market, reaching USD 3.33 billion in 2025. High lymphoma prevalence, advanced therapeutics, strong healthcare spending, and extensive clinical research are supporting regional growth. The U.S. remains a major contributor due to rapid adoption of innovative lymphoma treatments and strong pharmaceutical R&D.

Europe

Europe is expected to remain the second-largest regional market, supported by increasing use of advanced therapeutics and a substantial patient population requiring lymphoma treatment. The region is anticipated to grow at 7.9% during the forecast period.

Asia Pacific

Asia Pacific is expected to record the fastest regional growth. A large patient population, expanding healthcare infrastructure, and increasing approvals of advanced lymphoma therapies are creating substantial opportunities. Japan's market is projected to reach USD 930.5 million in 2025, while China is projected to experience strong growth.

Latin America and Middle East & Africa

Latin America is gradually developing as lymphoma prevalence increases and access to therapeutic products improves. Middle East & Africa is expected to experience comparatively slower development, although rising healthcare expenditure and growing demand for advanced cancer treatments will create future opportunities.

Competitive Landscape

The lymphoma treatment market includes Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, Novartis AG, Kite Pharma/Gilead Sciences, Spectrum Pharmaceuticals, Teva Pharmaceutical Industries, Bristol Myers Squibb, Janssen Pharmaceuticals, Genentech/Roche, Celgene, Merck & Co., Kyowa Kirin, AbbVie, and Sanofi. Leading companies are strengthening their positions through diversified oncology portfolios, clinical trials, regulatory approvals, and pipeline development.

Key Industry Developments

Recent developments have focused on regulatory submissions, CAR-T and immunotherapy advances, and clinical evidence for lymphoma treatments. Bayer advanced regulatory applications involving copanlisib and rituximab, Novartis reported positive ELARA trial results for Kymriah in relapsed or refractory follicular lymphoma, and Bristol Myers Squibb received U.S. approval for an immunotherapy for certain lymphoma patients.

Report Coverage

The lymphoma treatment market report covers market size and market value for 2025, 2026, and 2034, along with therapy and disease-type analysis, distribution channels, regional performance, pipeline analysis, regulatory developments, prevalence considerations, economic burden, reimbursement scenarios, new product launches, and competitive strategies. The report also evaluates key factors influencing the adoption of advanced lymphoma therapeutics.

Conclusion

The lymphoma treatment market is expected to expand significantly through 2034, supported by rising disease prevalence, advances in immunotherapy and targeted therapy, and strong pharmaceutical R&D activity. Immunotherapy is positioned as a major treatment segment, while non-Hodgkin lymphoma continues to represent the dominant disease category. North America maintains its leading position because of advanced healthcare infrastructure and high treatment adoption, while Asia Pacific offers substantial future opportunities due to its large patient population and increasing access to innovative therapies.

Unit Value (USD billion)

Segmentation By Therapy

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Others

By Disease Type

• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Lymphoma - by Key Countries - 2025
• 4.2. Pipeline Analysis
• 4.3. Key Industry Developments
• 4.4. Regulatory Scenario, by Key Regions
• 4.5. Analysis of Economic Burden of Lymphoma
• 4.6. New Product Launches
• 4.7. Overview of Emerging Treatments for Lymphoma

5. Global Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Therapy
  • 5.2.1. Immunotherapy
  • 5.2.2. Targeted Therapy
  • 5.2.3. Chemotherapy
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Type
  • 5.3.1. Non-Hodgkin Lymphoma
  • 5.3.2. Hodgkin Lymphoma
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Therapy
  • 6.2.1. Immunotherapy
  • 6.2.2. Targeted Therapy
  • 6.2.3. Chemotherapy
  • 6.2.4. Others
• 6.3. Market Analysis - By Disease Type
  • 6.3.1. Non-Hodgkin Lymphoma
  • 6.3.2. Hodgkin Lymphoma
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Therapy
  • 7.2.1. Immunotherapy
  • 7.2.2. Targeted Therapy
  • 7.2.3. Chemotherapy
  • 7.2.4. Others
• 7.3. Market Analysis - By Disease Type
  • 7.3.1. Non-Hodgkin Lymphoma
  • 7.3.2. Hodgkin Lymphoma
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis - By Country/ sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Therapy
  • 8.2.1. Immunotherapy
  • 8.2.2. Targeted Therapy
  • 8.2.3. Chemotherapy
  • 8.2.4. Others
• 8.3. Market Analysis - By Disease Type
  • 8.3.1. Non-Hodgkin Lymphoma
  • 8.3.2. Hodgkin Lymphoma
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis - By Country/ sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Therapy
  • 9.2.1. Immunotherapy
  • 9.2.2. Targeted Therapy
  • 9.2.3. Chemotherapy
  • 9.2.4. Others
• 9.3. Market Analysis - By Disease Type
  • 9.3.1. Non-Hodgkin Lymphoma
  • 9.3.2. Hodgkin Lymphoma
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis - By Country/ sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Therapy
  • 10.2.1. Immunotherapy
  • 10.2.2. Targeted Therapy
  • 10.2.3. Chemotherapy
  • 10.2.4. Others
• 10.3. Market Analysis - By Disease Type
  • 10.3.1. Non-Hodgkin Lymphoma
  • 10.3.2. Hodgkin Lymphoma
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis - By Country/ sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Takeda Pharmaceutical Company Limited
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. AstraZeneca
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Bayer AG
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Novartis AG
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Spectrum Pharmaceuticals, Inc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Bristol Myers Squibb Company
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Janssen Pharmaceuticals, Inc.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Merck & Co., Inc.
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Spectrum Pharmaceuticals, Inc.
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)
  • 11.5.11. Other Prominent Players
    • 11.5.11.1. Overview,
    • 11.5.11.2. Products & services,
    • 11.5.11.3. SWOT analysis,
    • 11.5.11.4. Recent developments,
    • 11.5.11.5. strategies,
    • 11.5.11.6. financials (based on availability)

12. Strategic Recommendations